<DOC>
	<DOCNO>NCT01658228</DOCNO>
	<brief_summary>Patients present depression ( DEP ) cognitive impairment ( CI ) , represent unique , understudied population difficult diagnose , treat estimate prognosis . Our pilot data , support literature , suggest many DEP-CI patient show cognitive decline often convert dementia , primarily Alzheimer 's disease ( AD ) . In DEP-CI , lack data treatment response mood symptom antidepressant treatment particularly cognitive deficit cognitive enhancer treatment . Our initial pilot data double-blind study show donepezil superior placebo improve memory antidepressant-treated DEP-CI patient . In second pilot study , open label es-citalopram plus memantine treatment lead low rate conversion dementia . In proposed pilot clinical trial , investigator evaluate , treat follow broad sample 80 DEP-CI patient NYSPI/Columbia University Medical Center ( N = 40 ) Duke University Medical Center ( N = 40 ) . Recruitment clinic and/or advertisement . In treatment protocol , 80 DEP-CI patient receive baseline mood memory assessment open antidepressant treatment citalopram 8 week . At 8 week , repeat assessment occur patient whose depression respond citalopram randomize add-on donepezil placebo . Non-responders citalopram receive open treatment venlafaxine randomize 8 week later ( 16 week open antidepressant treatment ) add-on donepezil placebo . Patients follow total period 18 month continuous open antidepressant treatment trial . Donepezil study order increase likelihood obtain signal . If result positive , investigator begin clarify mechanism ( ) subsequent trial . Baseline apolipoprotein E e4 genotype , odor identification deficit , MRI hippocampal entorhinal cortex atrophy explore predictor donepezil response 18-month trial . Improving cognition delay conversion clinical diagnosis dementia high risk group enhance quality life , reduce family burden , markedly diminish overall health care cost .</brief_summary>
	<brief_title>Combination Treatment Study Memory Impairment Depression</brief_title>
	<detailed_description>In elderly , common neuropsychiatric disorder depression ( DEP ) cognitive impairment ( CI ) . Their co-occurrence ( DEP-CI ) may exceed chance . The lack research DEP-CI , need determine early prognostic indicator , develop optimal treatment strategy , emphasize NIH consensus panel . Since depression patient CI increase risk conversion dementia , treatment strategy DEP-CI longer-term implication beyond acute antidepressant treatment response . However , DEP-CI , lack data treatment response mood symptom antidepressant treatment cognitive deficit cognitive enhancer treatment , long-term prognosis patient remain unclear . The investigator initial pilot data show donepezil superior placebo improve memory performance DEP-CI patient , pilot data show patient DEP-CI treat combined escitalopram memantine low conversion rate dementia , primarily Alzheimer 's disease ( AD ) , one year . This proposal first study explicitly examine cognitive change , include conversion dementia , randomize , double-blind , placebo-controlled donepezil treatment trial DEP-CI patient treat openly antidepressant . The investigator conduct systematic follow-up evaluate 18-month outcome . In addition apolipoprotein E ε4 genotype , investigator explore MRI hippocampal entorhinal cortex atrophy odor identification deficits biomarkers moderate response . This pilot trial enroll 80 DEP-CI patient present department Psychiatry , Neurology Internal Medicine NYSPI/Columbia University Duke University medical center , ensure broad representation clinical relevance . In treatment protocol , 80 DEP-CI patient receive open antidepressant treatment citalopram 8 week . At 8 week , citalopram responder continue treat citalopram , non-responders switch venlafaxine treatment additional 8 week . At 16 week , subject randomize add-on donepezil placebo ( N.B . Patients prior history nonresponse citalopram venlafaxine enrol protocol treat bupropion subsequently doctor 's choice antidepressant ) . Patients follow total period 18 month trial , antidepressant treatment adjust need base clinical response side effect , i.e. , open antidepressant treatment continuous subject throughout trial experimental intervention . The investigator choose study antidepressant plus donepezil compare placebo base pilot data increase likelihood obtain signal . Aim 1 ( primary aim study ) . To assess change cognitive status 18 month antidepressant-treated DEP-CI patient compare donepezil placebo . Hypothesis 1 . Antidepressant-treated DEP-CI patient donepezil show low rate conversion dementia , primarily AD , compare antidepressant-treated DEP-CI patient placebo end 18-month trial . Hypothesis 2 ( secondary ) . Compared placebo group , donepezil group show well cognitive outcome end 18-month trial ( SRT total recall : primary measure ; modify ADAS-cog : secondary measure ) . Hypothesis 3 ( secondary ) . At end 24 week add-on donepezil placebo , donepezil group show well cognitive outcome placebo ( SRT total recall : primary measure ; modify ADAS-cog : secondary measure ) . Aim 2 : To evaluate moderator treatment cognitive change 18-month donepezil-placebo trial , base view patient incipient AD brain pathology superior cognitive outcome donepezil . These Aim 2 hypothesis consider exploratory . Hypothesis 1 . Patients apolipoprotein E ε4 allele ( homozygote heterozygote ) , compare patient without allele , well cognitive outcome donepezil compare placebo . Hypothesis 2 . Lower score UPSIT ( odor identification test ) baseline associate well cognitive outcome donepezil compare placebo . Hypothesis 3 . Smaller MRI hippocampal entorhinal cortex volume ( atrophy ) associate well cognitive outcome donepezil compare placebo .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Of either sex , age 5595 year old minimum 8 year education meet criterion depression cognitive impairment describe . Study Criteria `` depression '' : . Patients meet DSMIV symptom criterion Major Depression Dysthymia minimum 6 month ( 2 year duration DSMIV TR criterion require dysthymic disorder study ) . ii . 24item HAMD ≥14 . Study Criteria `` cognitive impairment '' : i. Subjective memory cognitive complaint . ii . Score &lt; 11 Logical Memory II ( Delayed Paragraph Recall , Paragraph A ) test Wechsler Memory Scale Revised OR score ≥ 1.5 standard deviation norm FC SRT Folstein Mini Mental State ( MMSE ) score ≥ 21 30 . Clinical Dementia Rating ( CDR ) 0.5 memory item global rating 0.5 indicate questionable dementia Willing capable give informed consent A family member close friend consent serve informant study ; telephone informant case patient livein informant close significant . Meets Criteria dementia ( DSMIV ) probable Alzheimer 's disease ( NINCDSADRDA criterion ) Meets DSM IV TR criterion : 1. schizophrenia , schizoaffective disorder , psychotic depression psychosis , bipolar I disorder 2. alcohol substance dependence abuse ( current within past 6 month ) Active suicidal ideation suicidal attempt last 6 month . Clinical stroke residual neurological deficit . Use medication know negative impact cognition : benzodiazepine lorazepam equivalent ≥ 2 mg daily , narcotic , anticholinergic . ( N.B . Medications may associate cognitive impairment rarely consider likely etiology , e.g , theophylline , nifedipine , Beta blocker , exclude . ) An acute , severe unstable medical condition . For cancer , acutely ill patient ( include metastasis ) exclude , past history successfully treat cancer result exclusion . Presence follow disorder : ) CNS infection , CSF evidence meningitis , encephalitis , infectious process ; b ) Posttraumatic dementia , define dementia clear temporal relationship severe head injury consciousness lose ; c ) Huntington 's disease ; ) Multiple sclerosis ; e ) Parkinson 's disease ; f ) Other neurologic disorder focal sign , e.g. , amyotrophic lateral sclerosis ; g ) Mental retardation . Contraindication MRI scan : pacemaker , metal implant follow surgery , contraindication MRI ( e.g. , ferromagnetic aneurysm clip , heart valve ) . For patient possible claustrophobia , MRI adjunct lorazepam 0.5 mg reduce anxiety . Patients MRI scan still eligible clinical trial , i.e. , MRI optional .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Dysthymia</keyword>
	<keyword>Cognitive Impairment</keyword>
	<keyword>Cognitive Decline</keyword>
	<keyword>Memory</keyword>
</DOC>